A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression

PHASE2TerminatedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

May 4, 2017

Primary Completion Date

January 30, 2020

Study Completion Date

January 30, 2020

Conditions
PsychosisDementiaAggressionAgitationAlzheimer Dementia
Interventions
DRUG

MP-101

Capsules

DRUG

Placebo

Capsules

Trial Locations (20)

10312

Richmond Behavioral Associates, Staten Island

13057

Clarity Clinical Research, East Syracuse

32801

CNS, Orlando

33016

Galiz Research, Hialeah

33166

Galiz Research, Miami Springs

33486

Marcus Neuroscience Institute, Boca Raton

33613

University of South Florida, Tampa

33709

Meridien Research Inc, St. Petersburg

33980

Parkinson's Disease Treatment Center of SW Florida, Port Charlotte

34601

Meridien Research, Brooksville

45459

Neurology Diagnostics Inc, Dayton

66212

College Park Family Care Neuro, Overland Park

71104

J. Gary Booker, MD, Clinical Trials, Shreveport

85013

Dignity Health (St. Joseph Hospital and Medical Center), Phoenix

91105

Neuro-Therapeutics Inc, Pasadena

06824

Associated Neurologists of Southern CT, Fairfield

08759

Alzheimer's Research Corporation, Paterson

L3Y 5G8

SKDS Research Inc., Newmarket

H3A 2B4

Montreal Neurological Institute, Montreal

J1J 3H5

Centre de recherche sur le vieillissement du CIUSSS de l'Estrie - CHUS, Sherbrooke

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mediti Pharma Inc.

OTHER